Syndax Pharmaceuticals Inc
Compensation by Company
Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive
CompAnalyst Executive
For its 2022 fiscal year, Syndax Pharmaceuticals Inc, listed the following executives on its annual proxy statement to the SEC
|
Equity
Cash Compensation
Other
|
| Name And Title | Total Compensation | Pay Rank By Title In Biotechnology industry | |
|---|---|---|---|
|
Total Compensation $4,113,476 View details | Pay Rank By Title In Biotechnology industry #308 View more | |
|
Total Compensation $2,374,171 View details | Pay Rank By Title In Biotechnology industry #462 View more | |
|
Total Compensation $2,643,914 View details | Pay Rank By Title In Biotechnology industry #110 View more | |
|
Total Compensation $2,992,538 View details | Pay Rank By Title In Biotechnology industry #111 View more | |
|
Total Compensation $3,916,050 View details | Pay Rank By Title In Biotechnology industry #46 View more | |
|
Total Compensation $1,468,073 View details | Pay Rank By Title In Biotechnology industry #60 View more | |
|
Total Compensation $760,864 View details | Pay Rank By Title In Biotechnology industry #378 View more |
The charts on this page feature a breakdown of the total annual pay for the top executives at Syndax Pharmaceuticals Inc as reported in their proxy statements.
Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Syndax Pharmaceuticals Inc income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Syndax Pharmaceuticals Inc annual reports of executive compensation and pay are most commonly found in the Def 14a documents.
Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.
Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.
| Name And Title | Total Cash | Equity | Other | Total Compensation |
|---|---|---|---|---|
|
Total Cash $1,043,200 | Equity $3,062,276 | Other $8,000 | Total Compensation $4,113,476 |
|
Total Cash $972,188 | Equity $1,393,983 | Other $8,000 | Total Compensation $2,374,171 |
|
Total Cash $655,701 | Equity $1,980,213 | Other $8,000 | Total Compensation $2,643,914 |
|
Total Cash $436,650 | Equity $2,547,888 | Other $8,000 | Total Compensation $2,992,538 |
|
Total Cash $37,950 | Equity $3,878,100 | Other $0 | Total Compensation $3,916,050 |
|
Total Cash $597,820 | Equity $862,253 | Other $8,000 | Total Compensation $1,468,073 |
|
Total Cash $429,500 | Equity $323,364 | Other $8,000 | Total Compensation $760,864 |
| CEO Name | CEO Pay | Median Employee Pay | CEO Pay Ratio |
|---|---|---|---|
| Michael A. Metzger | CEO Pay $4,113,476 | Median Employee Pay $316,414 | CEO Pay Ratio 13:1 |
| Name | Total COMPENSATION |
|---|---|
| Dennis G. Podlesak | Total Cash $687,595 |
| Fabris Egros, PharmD, Ph.D. | Total Cash $260,403 |
| Jennifer Jarrett | Total Cash $306,980 |
| Keith A. Katkin | Total Cash $372,855 |
| Martin H. Huber, M.D. | Total Cash $309,565 |
| Pierre Legault | Total Cash $367,680 |
| William Meury | Total Cash $294,040 |
This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.
Use of Data / Disclaimer
The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.
What is a proxy statement?
A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.
The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.
